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An expandable donor-free supply of functional 
hepatocytes for Toxicology 
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Emma A. Fairhall,a Karen Wallace,a Michelle Charlesa Fiona Oakley,a Paul A. Jowsey,a 
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The B-13 cell is a readily expandable rat pancreatic acinar-like cell that differentiates on 
simple plastic culture substrata into replicatively-senescent hepatocyte-like (B-13/H) cells in 
response to glucocorticoid exposure.   B-13/H cells express a variety of liver-enriched and 
liver-specific genes, many at levels similar to hepatocytes in vivo.  Furthermore, the B-13/H 
phenotype is maintained for at least several weeks in vitro, in contrast to normal hepatocytes 
which rapidly de-differentiate under the same simple - or even under more complex - culture 
conditions.  The origin of the B-13 cell line and the current state of knowledge regarding 
differentiation to B-13/H cells are presented, followed by a review of recent advances in the 
use of B-13/H cells in a variety of toxicity endpoints.   B-13 cells therefore offer Toxicologists 
a cost-effective and easy to use system to study a range of toxicologically-related questions.  
Dissecting the mechanism(s) regulating the formation of B-13/H cell may also increase the 
likelihood of engineering a human equivalent, providing Toxicologists with an expandable 
donor-free supply of functional rat and human hepatocytes, invaluable additions to the tool kit 
of in vitro toxicity tests. 
 
 
 
Origin of the B-13 cell line 
The AR42J-B13 (henceforth referred to as the B-13) cell line 
was sub-cloned from the rat adenocarcinoma AR42J cell line in 
the late 1970s.  The AR42J cell line is an exocrine pancreatic 
adenocarcinoma cell line still used to the present day in basic 
exocrine pancreas research.1-6 The AR42J cell line was derived 
from studies in which inbred Wistar/Lewis rats were treated 
with azaserine (O-diazoacetyl-L-serine).7  Azaserine is a 
naturally occurring antibiotic first isolated from Streptomyces 
fragilis8 that causes cytotoxicity in cells through at least 2 
mechanisms:- inhibition of N-formylglycineamidine ribotide 
synthetase (PFAS, phosphoribosylformylglycinamidine 
synthase), which results in an inhibition of purine biosynthesis;9 
and through spontaneous decomposition to yield diazoacetate, 
which carboxymethylates DNA primarily on the O6 and N7 of 
guanine and the N3 of adenine.10-12  Azaserine is also an 
inhibitor of glucosamine-6-phosphate isomerase (GFPT1)9 and 
is often used experimentally in studies on hexosamine 
biosynthesis.13  A single intraperitoneal injection of 30 mg 
azaserine/kg body weight is capable of inducing adenoma and 
subsequently carcinoma in rats several months after exposure, 
primarily in the pancreas.14  Accordingly, azaserine has been 
used in the past to generate experimental models of pancreatic 
cancer.15-19  Why the pancreas is a target organ for tumours 
with azaserine however, remains unclear. 
 AR42J cells were isolated from tumour cells generated from 
the rat azaserine studies of Longnecker et al7 and were 
transplanted back into untreated rats of the same strain by 
subcutaneous and intraperitoneal injections up to five times.  
The transplanted cells were reported to be capable of forming 
tumours at the site of injection and in lung and liver in some 
recipients.7 The AR42J cell line generated was noted to express 
high levels of amylase and other pancreatic exocrine 
enzymes.20 For summary, see Fig. 1. 
 The B-13 cell line was sub-cloned from the AR42J cell line 
by the Kojima lab in 1996 and was reported to differentiate into 
insulin-producing pancreatic endocrine β-like cells in vitro after 
treatment with hepatocyte growth factor (HGF) and activin A.21 
More recently, this effect has been shown to require expression 
in B-13 cells of transcription factors Ngn3 together with 
Nkx6.1 or MafA.22 
 In 2000, Shen et al observed that the B-13 cell underwent a 
profound alteration in phenotype from the pancreatic exocrine-
like cell to an hepatocyte-like cell in response to glucocorticoid 
exposure.23 In this study, a coordinated change in B-13 
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phenotype to an hepatocyte-like (B-13/H) cell - and not simply 
an occasional aberrant expression of an hepatocyte gene -
appeared to be the case (see also Tables 1-3).  A series of 
reports subsequent to this discovery essentially confirm these 
observations and demonstrate that B-13/H cells express a 
variety of genes that are hepatocyte-specific or hepatocyte-
enriched, including expression of blood proteins, cytoskeletal 
proteins, metabolic enzymes, xenobiotic metabolising enzymes 
(both phase I and phase II) and transporter proteins (for details 
see Table 1-3). 
 
Mechanisms regulating B-13 differentiation into 
hepatocyte-like cells 
Progenitor nature of B-13 cells 
The B-13 cell line readily proliferates in simple cell culture 
media such as Dulbecco’s modified Eagle medium (DMEM) 
supplemented with serum (typically 10% (v/v)), with a 
doubling time of 30 +/- 7.3 hours.46  The cells do not require 
any of the culture modifications often associated with stem cell 
maintenance (such as fibroblast feeders, matrigel or colony 
selection during sub-culture to select for progenitor 
characteristics).  The cells will readily expand on plastic 
substrata and appear to have an altered - but stable - near 
tetraploid karyotype of male origin.27  It is unknown for how 
long this karyotype has been stable, however B-13 cells have 
been repeatedly trans-differentiated into B-13/H cells for last 15 
years, suggesting alterations at the genomic DNA level are very 
stable.  B-13 cells do not grow in agar in vitro, and do not 
readily form tumours in SCID mice.  However, B-13 cells are 
capable of selectively engrafting into the pancreas and liver 
after intravenous injection, and spontaneously forming 
hepatocyte-like cells in the liver.27  B-13 cells therefore appear 
to retain some of the pathways that restrain dysregulated cell 
growth and differentiation.  Were it not for their unique ability 
to differentiate into hepatocyte-like cells, B-13 cells might be 
considered no different from any other cell line. 
 The liver and pancreas are thought to contain progenitor 
cells localised in the ductal regions of the tissue (Fig. 2).  Using 
the neural marker synaptophysin – which is expressed by B-13 
cells and suppressed in B-13/H cells,26 it is possible to identify 
putative progenitors in a limited number of both rat liver and 
pancreas ductal regions. The study of these progenitor cells in 
vitro is challenging since, in contrast to B-13 cells, the 
progenitor cells are difficult to purify and maintain as a pure 
population of progenitors.  In the rat, liver progenitors (oval 
cells) are bi-potential and give rise to hepatocytes and biliary 
epithelial cells (cholangiocytes) in vivo.85,86 In our hands, rat 
oval cells in culture rapidly generate biliary epithelial cells 
and/or fibroblasts (possibly through epithelial-mesenchymal 
trans-differentiation of biliary epithelial cells) and form a 
minority of the cell population within a day or two of isolation 
(Fig. 3). 
 The data to date suggest that the B-13 may be equivalent to 
a pancreatic or liver progenitor cell since it trans-differentiates 
from the B-13 acinar phenotype directly to the hepatocyte-like 
B-13/H phenotype.  Using a B-13 cell line stably transfected 
with a green fluorescent protein (GFP) gene under control of a 
promoter (which is trans-activated in exocrine pancreas cells) 
Shen et al23 showed that after exposure to glucocorticoid, cells 
could be identified that expressed both GFP and hepatocyte 
markers, suggesting that the mechanism of altered 
differentiation is likely a direct conversion from its 
“differentiated” pancreatic exocrine cell type directly to an 
hepatocyte, without reverting to a plastic progenitor-like 
intermediate).  However, more recently, limited evidence 
suggests that B-13 cells may be directed to form a ductal (i.e. 
biliary-like) phenotype in response to glucocorticoid and 
EGF.87  However, the identity of these cells is ambiguous, 
likely because the response lacks the quantitative trans-
differentiation response seen with B-13/H cells and 
hepatocytes.  This apparent plastic nature of B-13 cells may be 
reflective of the type of responses seen in a variety of cells in 
vitro, such as epithelial-mesenchymal transition (EMT), which 
commonly occur in vitro.88,89  However, whether B-13 cells 
enter (or are capable under certain circumstances of entering) a 
transient plastic state prior to conversion to B-13/H cells 
remains uncertain. 
 
Mechanism(s) mediating the formation of B-13/H cells 
 
There is good evidence to suggest that the glucocorticoid 
receptor (GR) mediates the response to glucocorticoid in B-13 
cells and initiates the process of trans-differentiation.  The 
synthetic glucocorticoid dexamethasone is frequently employed 
in generating B-13/H cells because it is less rapidly metabolised 
than natural glucocorticoids and is more selective for the GR 
than many natural glucocorticoids.29,30 However, B-13 cells 
respond similarly to a range other glucocorticoids and the 
response is inhibited by GR antagonists.23,90  Other classes of 
steroids (e.g. oestrogens) fail to promote the trans-
differentiation of B-13 cells into B-13/H cells90 (see also Fig. 4) 
and although glucocorticoids also activate the mineralocorticoid 
receptor,91 B-13 trans-differentiation to B-13/H cell does not 
occur in response to mineralocorticoids, nor is glucocorticoid-
dependent trans-differentiation blocked by mineralocorticoid 
receptor antagonists.92 
 Previous studies over the years have reported the 
appearance of hepatocyte-like tissue in pancreatic exocrine 
tissue in vivo, in response to a variety of pathological 
conditions (Table 4).  More recent observations have focussed 
on the effects of glucocorticoid on pancreatic exocrine tissue 
differentiation.  These studies have shown that both rodent and 
human embryonic acinar cells can be converted into 
hepatocyte-like cells in response to glucocorticoid in vitro.109,110  
However, of fundamental importance from a practical point of 
view, the quantitative functionality of these pancreatic 
hepatocyte-like cells to hepatocytes from the liver was rarely 
made.  When such comparisons were made, on a quantitative 
basis, it is arguable whether such cells could be defined as 
hepatocytes.  However, this lack of quantitative comparability 
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may be a feature of the in vitro environment in which the cells 
were cultured, and does not indicate necessarily that the cells 
were not capable of forming functional hepatocytes in the 
correct environment (such as  in vivo).  This is supported by 
recent studies in both rodents and man.24,90   
 Using in vivo models, Wallace et al demonstrated that 
treatment with high doses of glucocorticoid to adult rats for just 
a few weeks is enough to convert occasional pancreatic acinar 
cells into cells that express liver-levels of CYP2E1.24  In a 
transgenic mouse with high circulating endogenous circulating 
glucocorticoids and which showed many of the clinical features 
of Cushing’s disease, significant liver-levels of hepatocyte gene 
expression could be observed in the pancreata of many mice by 
adulthood (21 weeks of age).107  The normal pancreas is 
therefore capable of altering to an hepatocyte-like phenotype 
that shows comparable levels of hepatocyte gene expression in 
vivo when exposed to pathologically high levels of 
glucocorticoid.  Interestingly, these data also show that such a 
phenomenon is not restricted to embryonic or foetal tissue.  
Recent investigations also indicate that pancreata from adult 
patients maintained on high levels of systemic glucocorticoid 
therapy also express hepatocyte levels of hepatocyte expressed 
genes,90 suggesting that the observations in rodents are likely 
translatable to man. 
 Although it was clear from the first observations by Shen et 
al that the liver-enriched transcription factor CCAAT/enhancer-
binding protein-β (CEBP-β) was a pivotal downstream 
mediator of B-13 trans-differentiation to B-13/H cells,23 the 
signalling pathways that lead from glucocorticoid to the 
induction of this transcription factor in B-13 cells are only 
recently being determined.  Wallace et al provide strong 
evidence to suggest that GR activation in B-13 cells leads to a 
robust induction of the serine/threonine kinase SGK192 and that 
this kinase, at least in part, phosphorylates the Wnt signalling 
protein messenger β-catenin as a component of the mechanism 
that precedes induction of transcription factors such as CEBP-β 
(see also Fig. 5c for schematic diagram of proposed proximal 
mechanism of trans-differentiation).48,29 
 The physiological function of SGK1 in vivo is in the 
regulation of sodium salt re-absorption by the kidney.  The 
kinase functions to mediate mineralocorticoid stimulation of 
renal sodium channel (ENaC) activity and anti-natriuresis 
through its phosphorylation of the ubiquitin ligase Nedd4-2, 
which leads to a block in epithelial ENaC ubiquitylation, a 
reduction in ENaC endocytosis and increased renal tubular 
epithelial sodium transport into the cell.111  SGK1 mediates a 
stress response to low salt levels, promoting salt re-absorption.  
Accordingly, knockout of the Sgk1 gene in mice has no overt 
effect on mice unless the mice are forced onto a low salt 
intake.112,113   To date, a role for SGK1 in cell differentiation 
and/or tissue development – with the exception of B-13 cells - 
has not been identified.  However, a limited microarray study 
that compared the levels of approximately 5000 transcripts in 
B-13 and B-13/H cells identified SGK1 as the highest induced 
transcript in response to glucocorticoid treatment 
[supplementary data to Wallace et al24].  Subsequent studies 
demonstrated that expression of either of 2 human SGK1 
variants (but not the “wild type” variant A) alone, drove B-13 
trans-differentiation into B-13/H cells (see also Fig. 5).92  The 
SGK1 variants are identical with the exception of alternative N-
terminal domains.  These differentiation-promoting SGK1 
variants are also induced in both mouse and human pancreatic 
acinar hepatic tissue or cells after exposure to high 
glucocorticoid.107,90  Using recombinant SGK1 and β-catenin, it 
was shown that SGK1 was able to phosphorylate β-catenin on 
the residues that target β-catenin for ubiquitination and 
degradation,92 a process that would be expected to down-
regulate the Wnt signalling pathway.  A Wnt signalling-
responsive promoter-reporter gene construct suggested that Wnt 
signalling activity was highly active in B-13 cells.48  Inhibition 
of Wnt signalling (using the inhibitor quercetin or through 
over-expression of a mutant β-catenin [pt-Xβ-cat]) or siRNA to 
knockdown β-catenin expression) alone resulted in Cebp-β 
induction and trans-differentiation of B-13 cells into B-13/H 
cells.48 It is likely therefore, that specific Sgk1 variants provide 
the link between GR activation and the Wnt signalling pathway, 
and that this crosstalk lies upstream of Cebp-β induction and 
trans-differentiation.  In normal cells, this cross talk is unlikely 
to be operational and is only relevant in pathological situations 
such as chronic hyper-elevated glucocorticoid levels.  However, 
the Sgk1 cross talk with Wnt signalling may be amplified in 
some way in B-13 cells (e.g. through an over-induction and/or 
sustained elevation in SGK1 expression and/or a constitutively 
active PI3 kinase signalling pathway) such that the crosstalk 
mechanism is responsive in B-13 cells at physiologically 
normal concentrations of glucocorticoid.   
  
Notable features of B-13/H cell formation 
 
There are several features of the trans-differentiation of B-13 
cells into B-13/H cells that are striking, particularly in the 
context of current attempts to generate functional hepatocytes 
from embryonic stem cells or induced pluripotent stem cells for 
use in hepatology or toxicology research. 
 
 Treatment with glucocorticoid is sufficient to promote 
the trans-differentiation of B-13 cells into B-13/H cells. This 
contrasts markedly with the range of different growth factors 
and other poorly defined additions (e.g. matrigel, fibroblast 
feeder layers) that are required or often used when ESCs or 
iPSCs are directed to differentiate into hepatocyte-like cells in 
vitro.  Recombinant growth factors are also relatively expensive 
to produce and purify and are subject to variable functional 
activity, whereas glucocorticoids are inexpensive and relatively 
simple, stable chemicals. 
 A major physiological function of glucocorticoids is as a 
regulator of general metabolism.  Glucocorticoids are 
synthesised by the adrenals and the levels secreted into the 
blood are controlled by the hypothalamus-pituitary-adrenal 
(HPA) axis.114   Glucocorticoids are stress hormones and high 
levels promote gluconeogenesis, lipolysis and protein and 
amino acid degradation.114  Glucocorticoids also promote 
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diuresis and have a general immunosuppressive (most notably, 
anti-inflammatory) effect, a feature that is often employed for 
therapeutic reasons.115  However, glucocorticoids also have a 
developmental role, at least within the foetus.  Circulating 
levels of glucocorticoid are low in the embryo and foetus 
(placental enzymes such as 11β-hydroxysteroid dehydrogenase 
[HSD2] metabolise glucocorticoids to inactive products and 
foetal levels only rise as the foetal HPA axis develops).116,140  
This rise in circulating foetal glucocorticoid probably plays a 
major role in cell differentiation and tissue maturation, most 
notably in the lung, since premature babies are successfully 
treated with glucocorticoids to promote lung maturation.117 
 A biologically relevant GR activating concentration of 
glucocorticoids (typically 10-8 M) is sufficient to promote the 
trans-differentiation of B-13 cells into B-13/H cells. The 
affinity of the rat GR for dexamethasone is in the 10-9 M range 
(KD = 2.3nM118) and typically, 10-8 M dexamethasone is 
employed to robustly activate the GR in cells in vitro.  The GR 
is expressed in B-13 cells, is transcriptionally functional and its 
activity and apparent ability to drive B-13/H formation at 10nM 
dexamethasone is blocked by GR antagonists.90,119  In primary 
pancreatic rodent and human acinar cell cultures, significantly 
higher (10-6 to 10-5 M) concentrations are required (and produce 
a quantitatively much reduced trans-differentiation to 
hepatocyte-like phenotype).87,90  The reason(s) for this are 
unclear.  Although there is another receptor protein for 
dexamethasone in the rat with a lower affinity for 
dexamethasone (KD = 59nM118), the antagonist RU486 does not 
block dexamethasone binding to this protein, whereas RU486 
blocks primary pancreatic rodent and human acinar cell trans-
differentiation to hepatocyte-like cells.23,92  These observations 
therefore suggest that the activated GR may be hyper-functional 
in B-13 cells, although the reason(s) for this remain to be 
elucidated.  
 Exposure of B-13 cells to glucocorticoid converts the 
majority of the cells into a non-replicative B-13/H 
phenotype, with often less that 5% of the cells remaining in 
a B-13 phenotype.  From a practical point of view, a striking 
feature of hepatocyte-like cell generation from B-13 cells is the 
near complete trans-differentiation of B-13 cells to B-13/H cells 
in response to glucocorticoid.  It is therefore possible to 
generate a near pure population of hepatocyte-like cells with 
relative ease.  This contrasts with the potential for ESCs and 
iPSCs to differentiate into a variety of cells, although protocols 
are beginning to address this problem and hepatocyte purity has 
increased from early reports.   
 Although the liver has the capacity to regenerate in vivo 
through mitosis of existing hepatocytes in vivo, hepatocytes in 
culture do not readily undergo mitosis in vitro.119  Through 
additions of growth factors, low seeding densities etc, it is 
possible to stimulate DNA synthesis in cultured hepatocytes, 
but hepatocytes rarely complete the cell cycle in vitro and 
therefore, the cells are not readily expanded in vitro in the way 
that replicative cells lines may be expanded.119,120  In this 
respect, it is possible that the de-differentiation of hepatocytes 
when they are cultured under conditions designed to promote 
growth, has the effect of pushing them into the cell cycle from 
which they cannot emerge.121  In contrast, avoiding this 
regenerative-like response through culturing cells in sandwich 
cultures of extracellular matrix and/or 3D matrices may explain 
their superiority in maintaining hepatic function in culture [51-
53].122-124 
 B-13 cells are resistant to differentiation into other cell 
types in response to typical differentiating factors such as 
soluble growth factors and cytokines. In the liver, the 
progenitor cell (termed oval cell in rodents) is bi-potential and 
capable of differentiating into either hepatocytes or biliary 
epithelial cells.85,86  It is thought that oval cells only give rise to 
significant numbers of hepatocytes in liver regeneration when 
hepatocytes are prevented from undergoing mitosis 
themselves.85,86 If the B-13 cell is derived or markedly related 
in function to a pancreatic/hepatic progenitor, then one might 
expect that the B-13 cell be capable of differentiating into other 
pancreatic and/or hepatic cell types. 
 B-13 cells have been directed toward a pancreatic β cell 
phenotype although there appears to be a requirement for 
ectopic over-expression of specific transcription factors.21,22,125  
Treating B-13 cells with glucocorticoid and then EGF also 
promotes a ductal-like phenotype.87   
 Since it is arguably the case that many cell types can be 
forced to alter their phenotype into other cell types if the 
appropriate transcription factors are over-expressed (often 
referred to as direct lineage conversion126:- the induction of 
pluripotency by c-Myc, Klf4, Oct4 and Sox2127,128 being 
effectively direct linear conversion to pluripotent stem cells / 
indirect linage conversion to other mature cells), then it may 
not be surprising that B-13 cells can be directed into 
phenotypes other than hepatocytes when given the required 
non-hormonal signals, if sufficiently potent.  However, in all 
cases so far, the quantitative comparable functional 
differentiation of B-13 cells into other cell types in response to 
hormonal factors alone, does not compare with the robust 
response seen with respect to glucocorticoid and hepatocyte-
like cell formation.  Thus, B-13 cells resist differentiation into 
other cell types in response to typical differentiating factors 
such as soluble growth factors and cytokines. 
 B-13/H cells are quantitatively similarly functional to 
freshly isolated rat hepatocytes. As outlined above, a marked 
feature of B-13/H formation from B-13 cells is their 
quantitative comparability to primary rat hepatocytes.  This 
feature is relevant in particular, when considering in vitro cell 
models for studying toxicity mechanisms and potentially using 
the model to screen for drug and chemical toxicity. 
 Most chemical toxicities (both cytotoxic and genotoxic) in 
man are the result of metabolic activation in a target tissue(s) 
because exposure to directly cytotoxic reactive chemicals are 
normally avoided.129   A major driver of activation pathways is 
the level of expression of gene products associated with pro-
toxin activation.  In simplistic terms, expression of genes 
associated with metabolic activation are required to be 
expressed at levels at least approximating to those found in the 
target organ(s) for the cells to be a realistic in vitro model for 
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toxicity assessment.  This remains only an initial requirement 
since, additional layers of complexity would need to be taken 
into account (e.g. toxicokinetics, protective pathways etc) 
before such in vitro models could be used to predict in vivo 
toxicity. 
Conclusions 
The B-13 cell line provides an expandable donor-free supply of 
functional rat hepatocyte-like cells that can be readily used 
without a requirement for expertise found outside the average 
toxicology laboratory.  There remain some limitations to B-
13/H cells, such as the fact that they are rat cells and not 
human, and that there are limitations in the expression of some 
transporters such as NTCP.  However, given their ease of use 
and cost effectiveness, on balance B-13 cells have clear value 
in toxicity testing.  Loss of some genes, such as CYP1A2, can 
be overcome through ectopic expression (e.g. the human gene).  
Furthermore, understanding the unique features of this cell line, 
when applied to human stem cell-derived hepatocytes, may also 
be essential in the drive toward generating more functional and 
stable hepatocytes in vitro.  
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 Table 1. Hepatocyte phenotype in B-13/H cells, utility in hepatotoxicity studies – blood 
proteins, cell structure and metabolism. 
Gene Method of analysis Comment 
Blood proteins   
Albumin ICC,23 RT-PCR,24 WB,25,27 
secretion ELISA26 
Hepatocyte-specific, major blood protein.30 
Transferrin ICC,23 RT-PCR,24 WB26 Hepatocyte-enriched, also expressed by other tissues such as the brain and testis.  
Functions as an iron transporter.31 
Transthyretin ICC,23 RT-PCR24 Hepatocyte-enriched, also expressed by chorioid plexus and retinal pigment 
epithelium.  Functions as a thyroid hormone transporter.32 
α1-antitrypsin ICC23  Hepatocyte-enriched, but also expressed in monocytes, macrophages, pulmonary 
alveolar cells, and by intestinal and corneal epithelium .  Protease inhibitor that 
functions to inhibit elastases as well as other proteases.33 
Α2-macroglobulin (αMG) ICC,25 RT-PCR,25 WB25 Hepatocyte-enriched, also expressed in macrophages, fibroblasts, and adrenocortical 
cells.  Acute phase response protein, broad spectrin protease inhibitor, functions to 
inhibit fibrinolysis.34 
Haptoglobin (Hp) ICC,25 RT-PCR,25 WB25 Hepatocyte-enriched, also expressed in skin, kidney and lung.  Acute phase response 
protein, functions to bind and transport free haemoglobin.35 
𝛼-fetoprotein ICC23  Foetal yolk sac and liver-specific (low levels in intestines), blood protein associated 
with foetus.36  Expression in B-13/H cells not confirmed in other studies by RT-
PCR.24,29 
Apolipoprotein B ICC26 Serves as ligand for the LDL receptor.  Full length ApoB100 is expressed specifically 
by the liver.37  
Cell structure   
Cytokeratin 8 (CK8) ICC23 Structural protein associated with secretory epithelium such as hepatocytes.38 
Metabolism   
Glucose 6 phosphatase ICC,23 RT-PCR 24 Liver enriched, also expressed in, kidney, intestine, and pancreatic islets .39 
Tyrosine aminotransferase RT-PCR 24 Liver –specific.  This gene is transcriptionally regulated by the GR.40 
Arginosuccinate synthase RT-PCR 24 Urea cycle enzyme, expressed predominantly in the liver but is also expressed in most 
other tissues such as fibroblasts, kidney, heart, brain, muscle, pancreas, and red blood 
cells.41 
Carbamyl synthetase (CPSI) RT-PCR,24 WB,24,26,27 ICC27 CPSI is a urea cycle enzyme expressed in rat liver throughout much of the lobule but 
not in proximal centrilobular hepatocytes.42,43  B-13/H cells positive for CPSI were 
negative for glutamine synthase by ICC.28 
Glutamine synthase (GS) ICC28 Ammonia removing enzyme, GS is expressed in rat liver only in the in proximal 
centrilobular hepatocytes.42,43  B-13/H cells positive for GS were negative for CPSI.28 
Ornithine transcarboxylase RT-PCR25 Urea cycle enzyme.43 
Glucokinase  ICC28 Expressed in liver and other tissues.44 
ICC, immunocytochemistry; RT-PCR, RT-PCR determination; WB, Western blotting; ELISA, enzyme linked immunosorbent assay-based determination. 
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Table 2.  Hepatocyte phenotype in B-13/H cells, utility in hepatotoxicity studies – xenobiotic 
metabolism and related. 
Gene Method of analysis Comment 
Xenobiotic metabolism and 
related 
  
CYP450 reductase WB45,26 Essential for functional microsomal cytochrome P450 activity.49  Required for 
toxic effects of many drugs and chemicals.129 
Total CYP450 SPEC45,27 Major xenobiotic metabolising gene superfamily.50  Reduced CO versus reduced 
spectra peak at 450nm.  It is possible to generate cells with similar levels to rat 
hepatocytes detectable.27 Required for toxic effects of many drugs and 
chemicals.129 
Cytochrome b5 SPEC Unpublished. 
Aryl hydrocarbon receptor 
(AhR) 
RT-PCR46  Receptor for polyaromatic hydrocarbon xenobiotics – regulates induction of 
CYP1 genes.51 
Aryl hydrocarbon receptor 
nuclear translocator (AhRNT) 
RT-PCR46 Heterodimerizes with AhR , essential for effective AhR-mediated transcriptional 
function.51 
CYP1A1 RT-PCR,46 WB,46 FUNC46. Expression induced by AhR activator β-naphthoflavone.46  See also Fig. 6.  
Required to generate genotoxic products from many polyaromatic hydrocarbons 
such as benz(α)pyrene.46 
CYP1A2 Absent - RT-PCR,46 absent – 
WB,46 absent – FUNC46 
All alleles appear disrupted in cell line.46  Expression of human CYP1A2 mediates 
PhIP activation to a genotoxic product.46 
Constitutive androstane 
receptor (CAR) 
RT-PCR46 Transcriptional regulator of CYP2B induction response .52 
CYP2B1 RT-PCR,46 absent – WB,46 
present WB,26 ICC,28 absent – 
FUNC46  
CAR activators result in induction in mRNA expression, but translation is 
lacking.46  See also Fig. 6.  Note, CYP2B1 is not constitutively significantly 
expressed in rat hepatocytes, only after administration of inducers .53 
CYP2B2 Absent - RT-PCR,46  ICC29 CYP2B2 is constitutively expressed at only low levels in rat hepatocytes.53 
CYP2A1/2 WB45  
CYP2C6 RT-PCR, 24,46 WB46 An adult hepatic gene expressed at high and similar levels in both male and 
female rats.54 
CYP2C11 RT-PCR, 45,46 WB,45,46 FUNC45 CYP2C11 is the major (male-specific) adult hepatic cytochrome P450.  
Expression is liver-specific.55  Metabolises methapyrilene to an hepatotoxic 
product,141 also observed in B-13/H, but not in B-13 cells.46 
CYP2C12 Low - RT-PCR46 CYP2C12 is the major (female-specific) adult hepatic cytochrome P450, 
Expression is liver-specific.55  Levels of mRNA in B-13/H cells are less than 1% 
of the levels seen in female rat liver.46  
CYP2C13 RT-PCR47 Male-specific isoform, specific to liver.56 
CYP2D1 RT-PCR47  
CYP2E1 RT-PCR,24,45,46, WB,24,26,45,48  
ICC,26,46 FUNC48 
Paracetamol is activated to a toxic metabolite.45 
Pregnane X receptor (PXR) RT-PCR,46 FUNC46 Receptor for drugs and xenobiotics – regulates induction of CYP3A genes.52  
Receptor regulates inducible expression of CYP3A sub-family – the orthologous 
sub-family in humans constitutes the predominant drug metabolising sub-family 
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responsible for the metabolism of approx. half of all drugs in man.50 
CYP3A1 RT-PCR, 46 WB,45,46,26 ICC 29 Inducible isoform.46 See also Fig. 6. 
CYP3A2 RT-PCR,46 WB,45 FUNC45 Adult liver-specific isoform, male predominant expression.57 
CYP3A9 RT-PCR46  
Peroxisome proliferator 
activated receptor α (PPARα) 
RT-PCR47 Receptor for peroxisome proliferator drugs such as fibrates – regulates induction 
of CYP4A genes.58 
CYP4A1 Absent - RT-PCR,47 absent – 
WB47 
Many CYP4A genes appear to be disrupted in B-13 cells – no induction of 
proteins - see Fig. 6. 
CYP4A2 Absent - RT-PCR47  
CYP4A3 Absent - RT-PCR47  
Farnesoid X receptor Low expression Unpublished.  Receptor for bile acids – regulator of bile acid synthesis.59 
CYP7A1 WB26  
Liver X receptor RT-PCR Both LXRα and LXRβ are expressed in B-13/H cells (unpublished).  
Transcriptionally functional in B-13/H cells (unpublished).  Receptor for 
oxysterols. 
Phase II enzyme systems   
Sulfotransferases (SULTs)  5/14 genes expressed at mRNA level.46  Activates estragole to a genotoxic product 
in B-13/H cells.79 
SULT1A1 ICC,23,29 RT-PCR46 Substrate is 4 nitrophenol.60   
SULT1B1 RT-PCR46 Substrate is 4 nitrophenol.60 
SUL2B1 RT-PCR46 Substrates are steroids and bile acids.60 
SULT4A1 RT-PCR46  
SULT5A1 RT-PCR46  
UDP glucuronyltransferases 
(UGTs) 
 5/8 hepatic genes expressed at mRNA level.46 
UGT1A1 RT-PCR46 Main conjugating enzyme of bilirubin and drugs such as the anticancer drug 
irinotecan.  Other substrates include estradiol.61 
UGT1A5 RT-PCR46 Transiently elevated in immature rat liver.62 
UGT1A6 ICC23 4 nitrophenol  is a substrate.61 
UGT1A7 n/d Paracetamol is a substrate.  However, expression is low in liver, expressed high in 
gut.63 
UGT1A8 RT-PCR46  
UGT2B1 RT-PCR46 Substrates include morphine and testosterone.64 
   
UGT2B3 RT-PCR46  
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Glutathione transferases 
(GSTs) 
RT-PCR46 15/21 genes expressed at mRNA level..46  Catalyze conjugation reactions between 
reduced glutathione (GSH) and electrophilic substrates.65 
ICC, immunocytochemistry; RT-PCR, RT-PCR determination; WB, Western blotting; FUNC, functional assay; n/d, not determined; SPEC, 
spectrophotometric determination.. 
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Table 3.  Hepatocyte phenotype in B-13/H cells, utility in hepatotoxicity studies – endobiotic and 
xenobiotic transporters. 
Gene Method of analysis Comment 
Transporters 
(endobiotic/xenobiotic related) 
  
Abcb11 (BSEP) Low - RT-PCR,46 FUNC,46 
ICC28 
Canalicular-localised transporter, mediates bile acid efflux.66  Inhibited by 
troglitazone.67 
Abcb1b (MDR1/pglycoportein1) RT-PCR,46 FUNC46 Canalicular-localised transporter, mediates efflux of digoxin, talinolol, quinidine and 
fexofenadine in man .68  Verapamil is an inhibitor in man.68  Higher mRNA levels in 
B-13/H than intact rat liver.46 
Abcb4 (MDR2/pglycoportein3) RT-PCR46  MDR2 is the rodent orthologue of human MDR3.  Canalicular-localised transporter 
that mediates the biliary excretion of phospholipids.69  Similar mRNA levels in B-13/H 
to intact rat liver.46 
Abcc1 (MRP1) RT-PCR,46 FUNC46 Mediates efflux of leukotrienes, oestrogen conjugates, vincritine, etoposide.70  Normal 
human hepatocytes lack detectable amounts of MRP1.71  Basolateral-localised in 
normal tissues.71  Higher mRNA levels in B-13/H than intact rat liver.46 
Abcc2 (MRP2) Low - RT-PCR,46 FUNC46 Canalicular-localised transporter, mediates efflux of amphiphilic conjugates, such as 
bilirubin glucuronides, glutathione conjugates, and sulfate conjugates.72 
Abcc3 (MRP3) RT-PCR,46 FUNC46 Basolateral-localised transporter,73 mediates  efflux of glutathione, sulphate and 
glucuronide conjugates, such as estradiol-17beta-glucuronide, bilirubin-glucuronides, 
and etoposide-glucuronide.73Higher mRNA levels in B-13/H than intact rat liver.46 
Abcc4 (MRP4) RT-PCR,46 FUNC46 Basolateral-localised transporter, possibly mediates transport of cyclic nucleotides 
such as cAMP);74 low affinity bile salt export; conjugated steroids and prostanoids.73  
Higher mRNA levels in B-13/H than intact rat liver.46 
Abcc5 (MRP5) RT-PCR,46 FUNC,46 Basolateral-localised transporter, possibly mediates transport of cyclic nucleotides 
such as cGMP74 although this has been questioned.73,75  Higher mRNA levels in B-
13/H than intact rat liver.46 
Abcc6 (MRP6) RT-PCR,46 FUNC46 Basolateral-localised transporter, predominantly expressed in the plasma membrane of 
the hepatocyte (and to a lesser extent in the kidney).76  Mutations in the gene cause a 
rare, recessive genetic disease, pseudoxanthoma elasticum.76  Similar mRNA levels in 
B-13/H to intact rat liver.46 
Abcg2 (BCRP) RT-PCR,46 FUNC46 Canalicular-localised transporter, mediates efflux transport of many 
chemotherapeutics, and involved in haem, folate and uric acid homeostasis.77  This 
transporter is often associated with stem/progenitor cells.77  Similar mRNA levels in B-
13/H to intact rat liver.46 
Slc10a1 (NTCP) Low - RT-PCR46  Basolateral -localised transporter, mediates uptake of bile salts, sulfated compounds,  
thyroid hormones, drugs and toxins.78  Protein levels are absent in B-13/H and many 
other cells in culture, limiting their usefulness in toxicity screening studies.79 
Slc22a1 (OCT1) Low - RT-PCR46 Basolateral -localised transporter, mediates uptake of organic cations.80  Expressed at 
high levels in liver.81 
Slc22a2 (OCT2) RT-PCR46 Basolateral -localised transporter, mediates uptake of organic cations.81  Expressed at 
high levels in kidney.81  Similar mRNA levels in B-13/H to intact rat liver.46 
Slc22a6 (OAT1) RT-PCR46 Expressed predominantly in the kidneys and localized exclusively to the basolateral 
membrane of proximal tubular cells.  Mediates the uptake of various small, negatively 
charged molecules, such as endogenous metabolites, toxicants, and numerous 
clinically used therapeutics - functions as an antiporter exchanging intracellular α-
ketoglutarate against extracellular organic anions and drugs.82    Similar mRNA levels 
in B-13/H to intact rat liver.46 
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Slc22a7(OAT2) Low - RT-PCR46 Expressed in liver and kidney.  Apical renal transporter in rat.82  It is unclear why 
OAT2 in humans and Oat2 in rodents show a basolateral versus apical localization in 
proximal tubules. The presumed localization of OAT2/Oat2 in the sinusoidal 
membrane of hepatocytes awaits an experimental proof .82 
   
Slc22a8 (OAT3) Low - RT-PCR46 Basolateral renal transporter in rat, also expressed in liver.82 
Slc22a9 (OAT5) RT-PCR46 Apical renal transporter in rat.82  Similar mRNA levels in B-13/H to intact rat liver.46 
Slco1a5 (OATP3) RT-PCR46 Basolateral-localised transporter, primarily expressed in the choroid plexus in rat.83  
Similar mRNA levels in B-13/H to intact rat liver.46 
Slco1a6 (OATP5) RT-PCR46 Basolateral-localised transporter, primarily expressed in the kidney in rat.83  Similar 
mRNA levels in B-13/H to intact rat liver.46 
Slco2b1 (MOAT) Low - RT-PCR46 Transporter for prostaglandins, leukotrienes and taurocholate.84 
ICC, immunocytochemistry; RT-PCR, RT-PCR determination; WB, Western blotting. 
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Table 4.  Reports for evidence for hepatocyte formation in the pancreas in vivo. 
Condition/treatment Species Comments 
Pancreatic liver regeneration93 Hamster Pancreatic regeneration was induced by maintaining animals on a methionine-deficient 
and i.p. treatment with 500mg/kg bw/day DL-ethionine for 8 days. On the ninth day, 
animals were returned to a full amino acid diet and given a single i.p. injection of 800 
mg/kg bw methionine.  Morphological alterations of cells in pancreas observed. 
Pancreatic liver regeneration / 
methyl clofenapate94 
Hamster Pancreatic regeneration was induced by maintaining animals on a methionine-deficient 
and i.p. treatment with 500mg/kg bw/day DL-ethionine for 8 days. On the ninth day, 
animals were returned to a full amino acid diet and given a single i.p. injection of 800 
mg/kg bw methionine. Treatment with the peroxisome proliferator methyl clofenapate 
resulted in peroxisome proliferationand increases in the expression of markers of 
peroxisome proliferation in the pancreas.  Cytochemical localization of catalase and 
immunofluorescence localization of enoyl-CoA hydratase suggested peroxisome 
proliferation occurred in pancreatic hepatocyte-like cells and not adjacent acinar, duct 
and islet cells. 
Ciprofibrate95 Rat Animals were treated with the peroxisome proliferator ciprofibrate at 10mg/kg bw/day 
for 60-72 weeks. Primarily a morphometric study demonstrating appearance of 
hepatocyte like cells localized adjacent to islets and penetrating into exocrine tissue. 
Copper depletion/repletion96 Rat Animals were fed a copper-deficient diet containing 0.6% D-penicillamine for 8-10 
weeks, followed by copper repletion.  Morphometric study combined with 
immunohistochemical staining for albumin and catalase (in pancreatic hepatocytes) 
and absence of pancreatic enzymes and hormones. Ciprofibrate also shown to induce 
peroxisome proliferation in the pancreatic hepatocytes. 
Copper depletion/repletion97 Rat Pancreatic hepatocytes shown to express CPSI and urate oxidase – genes expressed 
highly in hepatocytes. 
Copper depletion/repletion98 Rat Animals were maintained on a copper-deficient diet containing the copper-chelating 
agent triethylenetetramine tetrahydrochloride at 0.6% w/w for 7-9 weeks and then 
returned to normal rat chow.  This resulted in low mortality (10%); pancreatic 
depletion of acinar cells and the development of multiple foci of hepatocytes in all 
100% of rats - in some animals, liver cells occupied more than 60% of pancreatic 
volume within 6-8 weeks of recovery.  Albumin mRNA expression confirmed in 
hepatocyte containing pancreata. 
Cadmium chloride99 Rat Repeated sub cutaneous  injections of cadmium chloride resulted in the appearance of 
pancreatic hepatocytes based on  rat albumin and connexin 32 expression. 
Dioxin  (2,3,7,8-
tetrachlorodibenzo-p-dioxin, 
TCDD) treatment100 
Hamster Two or 6 intraperitoneal injections of 100μg/kg bw  at 4 week intervals induced 
pancreatic hepatocytes in 75% and 89% of the animals respectively. 
Copper depletion/repletion101 Rat Pancreatic hepatocytes appear in both male and female pancreata in this model.  Male 
pancreatic hepatocytes synthesize in all cells, the male liver (centrilobular-specific) 
alpha 2u-globulin under androgenic regulation.  Expression was reduced after 
orchiectomy.  
Copper depletion/repletion102 Rat CPSI and glutamine synthetase are co-expressed in pancreatic hepatocytes, in contrast 
to the liver where they show marked demarcation across the hepatic lobule.  
Expression confirmed at mRNA level 
Copper depletion/repletion103 Rats Carcinogens that cause nucleolar segregation in parenchymal cells of liver, also have 
the same effect in pancreatic hepatocytes.  Dietary administration of 2-
acetylaminofluorene (0.025%) for 12 to 32 weeks also led to the development of 
glutathione S-transferase-P-positive pancreatic hepatocytes in the pancreas.  Oval cell 
proliferation was observed in close association with pancreatic hepatocytes. 
Copper depletion/repletion104 Rats Expression of liver-enriched transcription factors during oval cell proliferation in the 
pancreas preceded the expression of albumin mRNA and subsequent differentiation of 
hepatocyte phenotype 
Genetic model - ectopic 
expression of keratinocyte 
growth factor105 
Mouse Insulin promoter-regulated KGF resulted in the appearance of hepatocytes within the 
islets in the pancreas. 
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Genetic model – ectopic 
expression of FGF8106 
Mouse Glucagon promoter-regulated expression of FGF8 resulted in the appearance of 
hepatocyte-like cells in the periphery of pancreatic islets. 
Dexamethasone treatment24 Rat Administration of dexamethasone i.p. resulted in the appearance of occasional 
hepatocytes in the pancreas after 3 weeks. 
Genetic model of elevated 
systemic glucocorticoid levels 
(Cushing’s disease)107 
Mouse Pancreatic hepatocytes appear by 21 weeks of age as determined by transcript analysis, 
WB and ICC.  Adrenalectomy prevents appearance of pancreatic hepatocytes. 
Genetic model – ablation of 
Sox9108 
Mouse Pancreatic progenitor-specific ablation of Sox9 during early pancreas development 
caused pancreas-to-liver cell fate conversion 
Resected human pancreas from 
patients maintained on long term 
systemic glucocorticoid 
therapy90  
Human Pancreatic hepatocytes observed in resected human pancreas from patients maintained 
on long term systemic glucocorticoid therapy, as determined by transcript analysis, 
WB and ICC. 
Note that the isolation and culture of rat or mouse acinar cells in vitro and treatment with glucocorticoid is also capable of inducing the expression of genes 
associated with the hepatocyte,138,139 although the levels of expression are not comparable to those seen in B-13/H cells. 
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Figure 1.  Origin of the AR42J and AR42J-B13 (B-13) cell lines.  Upper panels, light micrographs of the 
indicated cell line, lower panel, fluorescence immunocytochemical staining as outlined,48 note cytoplasmic staining 
of the CYP2E1, DAPI staining DNA and identifies the nucleus. 
 
Figure 2.  Localisation of putative synaptophysin positive progenitor cells in rat liver and pancreas.  A, 
schematic diagram of pancreas and liver tissue and potential analogous position of putative progenitors in the 
respective tissues.  B, immunohistochemical staining for syntaptophysin and DAB detection in rat pancreas (left 
panels) and liver (right panels) stained essentially as outlined.130  Dotted panel is expanded in lower panel; d, duct, 
pv, perivenous region; p, putative progenitor. 
Figure 3.  Isolation and culture of putative progenitor cells from rat liver results in generation of duct cells 
and fibroblasts.  Putative progenitor cells were isolated from pronase digestion of the bilary tree remaining after a 
two-step collagenase digestion of rat liver131  A, Light micropgraphs (upper panels) of cell types observed after 3 
days of culture.  Lower panels, immunocytochemical staining for progenitor (OV-6), ductal (CK-19 and fibroblast 
(vimentin) markers129 in the morphologically distinct cell types after 3 days of culture, stained essentially as 
described .48  B, RT-PCR analysis for the indicated transcript essentially as described.24,48 
Figure 4. Oestrogens do not affect B-13 cell differentiation via the ER or GR. Recent work has demonstrated 
that B-13 cells are capable of differentiating into ductal-like cells87 and that an alternative nuclear receptor – the 
oestrogen receptor-α (ERα) – mediates the effects of glucocorticoids in lumen-forming cells (such as the progenitor 
cells of the liver, which are bi-potential and capable of forming hepatocytes or the lumen-forming 
cholangiocytes).132  A, demonstrates that the mRNA for ERα as well as the related ER gene ERβ are not detectable 
in B-13 cells in contrast to rat hepatocytes (which are known to express ERα133) and uterus and the ovary (which 
has previously been reported to express the ERβ134). RT-PCR analysis for the expression of ERα and ERβ mRNA 
transcripts in 4 separate B-13 cell cultures, after 30 cycles essentially as described.24,48   B, transfection of an 
oestrogen receptor-responsive reporter gene construct (ERE3-pGL3promoter)135 into B-13 cells and treatment with 
either DEX or the natural endogenous oestrogen receptor activating ligand 17β oestradiol (E2) resulted in 
significant ERE3-pGL3promoter reporter gene expression in response to DEX*.  However, only the GR antagonist 
RU486 - and not two oestrogen receptor antagonists (tamoxifen or ICI182780) significantly inhibited DEX-
dependent increases in ERE3-pGL3promoter reporter gene expression$.  These data therefore suggest that DEX-
dependent activation of the GR is responsible for the increase in ERE3-pGL3promoter reporter gene expression, 
likely due to high GR expression in B-13 cells.  This is supported by alterations in phenotype (C) or expression of 
hepatic markers (D) as determined by Western blotting.24,48 
Figure 5.  Over-expression of SGK1F induces a trans-differentiation of B-13 cells to B-13/H cells without the 
addition of glucocorticoid.  B-13 cells were infected with an adenovirus encoding the human SGK1F isoform 
(AdV-SGK1F) which has been previously shown to direct B-13 differentiation into B-13/H cell,92 or a control 
adenovirus encoding NTCP (AdV-control) and morphology examined after 3 days (A) or cells harvested at day 5 
for Western blotting (B) for the indicated protein.24,48  Where indicated, cells were also treated with dexamethasone 
(DEX), the GR antagonist RU486 or the SGK1 antagonist GSK 650394 (GSK).136  For more details on variant 
SGK1 isoforms and methodology, see Wallace et al, including supplementary data.92  C, Schematic diagram 
illustrating the cross talk between the GR, SGK1 and WNT signalling pathways operating in B-13 cells. 
 
Figure 6.  Induction of hepatic cytochrome P450s in B-13, B-13/H and rat hepatocytes in vitro.  B-13, B-13/H 
and rat hepatocytes in culture were treated with established cytochrome P450 inducersdaily for 3 days  
(androstenol, 5μM; β-naphthoflavone [β-NF], 20μM; phenobarbitone [PB], 1mM; 1,4-Bis-[2-(3,5-
dichloropyridyloxy)]benzene, 3,3′,5,5′-Tetrachloro-1,4-bis(pyridyloxy)benzene  [TCPOBOP],  1.5μM; 
dexamethasone [DEX], 10μM; pregnenolone 16α carbonitrile [PCN], 2μM or bezafibrate, 250μM as outlined,46 
followed by Western blotting for the indicated protein. 24,48 
 
Figure 7.  PPARα-dependent peroxisomal proliferation, but not CYP4A induction, is functional in B-13/H 
cells.   DNA from B-13 cells was subjected to mate-pair library construction and SOLiD Whole Genome 
sequencing and analysed as outlined,46 A, illustrates significant insertions/deletions in the CYP4A locus which 
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likely explains lack of constitutive and bezafibrate-inducible expression of CYP4A genes as determined by RT-
PCR (B), qRT-PCR for CYP4A1 mRNA; primary hepatocytes and B-13/H cells were treated for 3 days daily or 
over 14 days (B-13/H cells only) with vehicle (0.1% (v/v) DMSO) or 250μM bezafibrate in DMSO from a 1000-
fold molar concentrated stock (C), bars are the mean and standard deviation of 3 independent determinations from 
a single experiment, typical of at least 3 separate experiments, *indicates significant difference compared to the 
indicated group at p<0.05.  and Western blotting (D), cells were treated for 3 days as outlined for B and harvested 
24 hours after the last treatment, results typical of 3 separate experiments.  All methodologies have been previously 
published.24,46,48  E, peroxisomal proliferation in response to bezafibrate treatment in B-13/H cells.  B-13/H cells 
were treated with vehicle (0.1% (v/v) DMSO) or 250μM bezafibrate for 14 days. Following treatment cells were 
immunostained for the peroxisomal memberane protein 70 (PMP70) marker137 essentially as previously 
described.46 The cells were then counterstained with DAPI. Cells were photographed using a Zeiss fluorescence 
microscope and staining quantified using ImageJ particle counter. Results were normalised to cell number. Results 
are the mean and SD of 5 fields of view from the same experiment, typical of at least 3 separate experiments. Scale 
bar indicates 48μm. *significantly different to vehicle control at p<0.05. 
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